3 Biotechs on the Move: FOLD, ARIA, and AST

Amicus Therapeutics, Inc. (NASDAQ:FOLD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), and Asterias Biotherapeutics Inc (NYSEMKT:AST) are following in the volatile path of the broader equities market

Aug 31, 2015 at 3:12 PM
facebook twitter linkedin

It's another volatile day in the U.S. equities market, as traders digest reports of stock market investigations overseas -- as well as central bank chatter stateside. Wall Street is also keeping a close eye on the energy sector, which is staging a phenomenal rebound following speculation OPEC could be making moves to stabilize oil prices. Amid all of this action, a number of equities in the ever-volatile biotech sector are making notable moves -- with some rallying to territory not seen in quite some time -- including Amicus Therapeutics, Inc. (NASDAQ:FOLD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), and Asterias Biotherapeutics Inc (NYSEMKT:AST).

FOLD made waves this morning when it was announced the company will purchase rare disease specialist Scioderm, Inc. for roughly $230 million in cash and stock. The news initially sent the shares 6.5% higher, although FOLD was last seen 3.1% lower at $14.41. Year-to-date, though, the shares still maintain an impressive gain of 73%.

In the options pits, short-term speculators have shown a distinct preference for calls over puts. In fact, Amicus Therapeutics, Inc.'s Schaeffer's put/call open interest ratio (SOIR) of 0.29 rests lower than 94% of all similar readings taken in the past year. Simply stated, speculative traders have rarely been as call-heavy toward FOLD as they are now.

After last Friday's rumors that Baxalta Inc (NYSE:BXLT) -- which recently shunned a buyout bid of its own -- is in talks to purchase ARIA, shares of the latter jumped to an annual high of $10.07 -- and into overbought territory. In fact, the stock's 14-day Relative Strength Index (RSI) settled the week at 73. This may be why ARIA is down 6.3% today at $9.27, paring its 2015 advance to 35%.

Option traders, meanwhile, have taken the glass-half-empty approach to Ariad Pharmaceuticals, Inc. in recent months. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), ARIA's 50-day put/call volume ratio of 0.71 ranks in the 83rd annual percentile. Given the security's year-to-date gain, though, some of this activity may be of the protective kind.

Unlike FOLD and ARIA, AST is soaring in afternoon action -- up 13.5% at $4.70. Sparking the day's risk-on attitude is data that showed promising results for its stem cell therapy -- specifically, on patients paralyzed by injuries to their spinal cord. Despite today's gap higher, the security stalled out near $5.50 -- a level that contained AST's advances in mid-July.

Short sellers are likely paying close attention to Asterias Biotherapeutics Inc's bull gap, considering 17% of the stock's float is sold short -- representing more than two weeks' worth of pent-up buying demand, at normal daily volumes. Should AST rally through previous resistance near $5.50, a capitulation from some of the weaker bearish hands could help propel the shares higher.

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!